The Galleri blood test, developed by Californian healthcare company Grail, will be piloted with 165,000 patients in what the NHS described as a “world-first deal” in a news release Friday.
Grail, whose work is focused on detecting cancer early, is backed by investors including tech billionaire Bill Gates and Amazon founder Jeff Bezos.
NHS England hopes the blood test will be particularly useful in identifying types of cancer that are currently difficult to diagnose and treat early.
“Early detection — particularly for hard-to-treat conditions like ovarian and pancreatic cancer — has the potential to save many lives,” said NHS chief executive Simon Stevens.
More than 1,000 people are newly diagnosed with cancer every day in the UK, he added.
The pilot program, due to start in mid-2021, will involve 165,000 people, including 140,000 aged from 50 to 79 who have no symptoms but will have annual blood tests over three years.
The remaining 25,000 participants will be people with possible…
— to www.cnn.com